clotrimazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	719	23593-75-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clotrimazole lotrimin rimazole locasten	An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. Molecular weight: 344.84 Formula: C22H17ClN2 CLOGP: 5 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 17.82 ALOGS: -5.37 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clotrimazole
lotrimin
rimazole
locasten

An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.

Molecular weight: 344.84
Formula: C22H17ClN2
CLOGP: 5
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 17.82
ALOGS: -5.37
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	V

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.07 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Feb. 3, 1975	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	452.65	13.31	157	11529	14231	50579207
Schizoaffective disorder	236.37	13.31	62	11624	2144	50591294
Drug level increased	124.78	13.31	69	11617	19199	50574239
Electrocardiogram QT prolonged	67.46	13.31	71	11615	51815	50541623
Sinus rhythm	45.36	13.31	13	11673	627	50592811
Vanishing bile duct syndrome	40.97	13.31	12	11674	625	50592813
Eye infection toxoplasmal	40.48	13.31	10	11676	270	50593168
Vulvovaginal candidiasis	39.88	13.31	17	11669	2675	50590763
Oral candidiasis	33.07	13.31	29	11657	16886	50576552
Purpura senile	29.82	13.31	9	11677	520	50592918
Vulvovaginal inflammation	28.68	13.31	9	11677	593	50592845
Tongue blistering	28.45	13.31	11	11675	1347	50592091
Febrile neutropenia	27.50	13.31	66	11620	97601	50495837
Tarsal tunnel syndrome	25.43	13.31	8	11678	531	50592907
Swollen tongue	23.54	13.31	31	11655	28599	50564839
Candida infection	23.37	13.31	28	11658	23495	50569943
Angiodermatitis	22.96	13.31	5	11681	76	50593362
Drug interaction	21.37	13.31	97	11589	199524	50393914
Post viral fatigue syndrome	20.80	13.31	6	11680	296	50593142
Resorption bone increased	20.51	13.31	8	11678	1003	50592435
Swelling of eyelid	18.81	13.31	9	11677	1851	50591587
Aplastic anaemia	18.77	13.31	15	11671	7688	50585750
Vestibular disorder	18.75	13.31	8	11678	1261	50592177
Reperfusion arrhythmia	17.59	13.31	5	11681	234	50593204
Therapeutic product effect decreased	17.26	13.31	5	11681	136045	50457393
Chronic sinusitis	17.22	13.31	13	11673	6132	50587306
Rheumatoid arthritis	17.18	13.31	13	11673	202537	50390901
Glossodynia	17.16	13.31	3	11683	115566	50477872
Stevens-Johnson syndrome	17.03	13.31	23	11663	21729	50571709
Conjunctivitis	15.68	13.31	19	11667	16126	50577312
Toxicity to various agents	15.19	13.31	16	11670	212483	50380955
Vulvovaginal discomfort	15.13	13.31	8	11678	2033	50591405
Congenital absence of bile ducts	15.12	13.31	3	11683	28	50593410
Dysuria	14.96	13.31	25	11661	28479	50564959
Neuropathy peripheral	14.31	13.31	52	11634	96705	50496733
Oedema mouth	14.26	13.31	8	11678	2282	50591156
Treatment failure	14.22	13.31	7	11679	137630	50455808
Swelling face	14.21	13.31	35	11651	52560	50540878
Stoma site haemorrhage	14.13	13.31	6	11680	935	50592503
Post transplant distal limb syndrome	14.05	13.31	4	11682	188	50593250
Foetal death	13.97	13.31	13	11673	8167	50585271
Urinary tract infection	13.95	13.31	94	11592	223926	50369512
Mouth ulceration	13.94	13.31	24	11662	28000	50565438
Vertigo positional	13.58	13.31	8	11678	2503	50590935
Exfoliative rash	13.52	13.31	8	11678	2522	50590916

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cellulitis	22.87	15.93	36	5792	45804	29522895
Skin infection	20.72	15.93	14	5814	6513	29562186
Lip haemorrhage	20.20	15.93	7	5821	738	29567961
Accident	19.62	15.93	11	5817	3677	29565022
Rash pruritic	19.44	15.93	23	5805	22340	29546359
Aplastic anaemia	18.95	15.93	14	5814	7496	29561203
Temperature regulation disorder	17.82	15.93	6	5822	580	29568119
Microtia	17.56	15.93	5	5823	277	29568422
Congenital umbilical hernia	17.37	15.93	5	5823	288	29568411
Lymphopenia	17.17	15.93	17	5811	13516	29555183
Leukopenia	16.83	15.93	35	5793	55168	29513531

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Vulvovaginal candidiasis	44.62	13.53	17	14096	2113	64482506
Aplastic anaemia	39.42	13.53	29	14084	13891	64470728
Eye infection toxoplasmal	35.53	13.53	10	14103	477	64484142
Vanishing bile duct syndrome	33.40	13.53	12	14101	1265	64483354
Oral candidiasis	32.00	13.53	32	14081	23180	64461439
Rash pruritic	31.68	13.53	50	14063	57354	64427265
Tongue blistering	29.55	13.53	11	14102	1282	64483337
Febrile neutropenia	26.70	13.53	96	14017	187561	64297058
Drug ineffective	26.41	13.53	95	14018	840152	63644467
Tarsal tunnel syndrome	26.37	13.53	8	14105	497	64484122
Purpura senile	26.28	13.53	8	14105	503	64484116
Toxicity to various agents	25.71	13.53	25	14088	363488	64121131
Swollen tongue	24.40	13.53	34	14079	34920	64449699
Angiodermatitis	23.36	13.53	5	14108	74	64484545
Candida infection	22.59	13.53	31	14082	31388	64453231
Stevens-Johnson syndrome	21.97	13.53	32	14081	34217	64450402
Post viral fatigue syndrome	21.08	13.53	6	14107	298	64484321
Swelling of eyelid	20.86	13.53	10	14103	2182	64482437
Gingival swelling	20.52	13.53	12	14101	3908	64480711
Overdose	20.23	13.53	5	14108	159561	64325058
Resorption bone increased	19.81	13.53	8	14105	1160	64483459
Vulvovaginal inflammation	18.38	13.53	6	14107	474	64484145
Urinary tract infection	18.06	13.53	99	14014	231497	64253122
Wound complication	17.85	13.53	11	14102	3937	64480682
Oral mucosal blistering	17.34	13.53	12	14101	5225	64479394
Reperfusion arrhythmia	16.87	13.53	5	14108	287	64484332
Lip haemorrhage	16.60	13.53	7	14106	1132	64483487
Plicated tongue	16.59	13.53	4	14109	103	64484516
Pruritus	15.98	13.53	120	13993	312280	64172339
Therapeutic product effect decreased	15.87	13.53	3	14110	115348	64369271
Cellulitis	15.12	13.53	50	14063	93607	64391012
Genital rash	14.90	13.53	6	14107	863	64483756
Swelling face	14.82	13.53	37	14076	59129	64425490
Kidney transplant rejection	14.77	13.53	14	14099	9497	64475122
Vestibular disorder	14.66	13.53	8	14105	2285	64482334
Vulvovaginal discomfort	14.51	13.53	7	14106	1548	64483071
Accident	14.47	13.53	12	14101	6834	64477785
Rash	14.20	13.53	158	13955	458391	64026228
Post transplant distal limb syndrome	13.94	13.53	5	14108	525	64484094
Nephrogenic systemic fibrosis	13.88	13.53	11	14102	5881	64478738
Vulvovaginal pain	13.83	13.53	7	14106	1715	64482904
Foetal death	13.81	13.53	11	14102	5919	64478700
Blister	13.77	13.53	44	14069	80923	64403696
Faeces discoloured	13.63	13.53	22	14091	25707	64458912
Mouth ulceration	13.58	13.53	25	14088	32419	64452200

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A01AB18	ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment
ATC	D01AC01	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives
ATC	G01AF02	GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives
FDA CS	M0002083	Azoles
FDA EPC	N0000175487	Azole Antifungal
CHEBI has role	CHEBI:35441	antiinfective agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:78298	environmental contaminants
MeSH PA	D058888	14-alpha Demethylase Inhibitors
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000891	Anti-Infective Agents, Local
MeSH PA	D000935	Antifungal Agents
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D065088	Steroid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tinea pedis	indication	6020002	DOID:12403
Candidiasis of skin	indication	49883006
Pityriasis versicolor	indication	56454009	DOID:9060
Candidal vulvovaginitis	indication	72605008	DOID:2272
Candidiasis of mouth	indication	79740000	DOID:14262
Tinea corporis	indication	84849002
Diaper rash	indication	91487003
Tinea cruris	indication	399029005
Prevention of Oropharyngeal Candidiasis	indication
Oropharyngeal Candidiasis	indication
Paronychia	off-label use	71906005	DOID:13117
Telangiectasia disorder	contraindication	247479008
Abdominal pain - cause unknown	contraindication	314212008
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Fungal infections caused by Microsporum canis	Indication
Cats	Fungal infections caused by Trichophyton mentagrophytes	Indication
Cats	Otitis externa caused by yeast, Malassezia pachydermatis	Indication
Dogs	Fungal infections caused by Microsporum canis	Indication
Dogs	Fungal infections caused by Trichophyton mentagrophytes	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Veltrim 1% Dermatologic Cream	Elanco US Inc.	1
Otomax	Intervet Inc.	3
Mometamax Otic Suspension	Intervet Inc.	3
Tri-Otic Ointment	Med-Pharmex Inc.	3
Vetro-Max	Fougera Pharmaceuticals Inc.	3
GBC Ointment	Cronus Pharma Specialities India Private Limited	3
Mometavet	Med-Pharmex Inc.	3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.4	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	5.19	DRUG MATRIX
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN		IC50	4.38	DRUG MATRIX
Nuclear receptor subfamily 1 group I member 3	Nuclear hormone receptor	Q14994	NR1I3_HUMAN	ANTAGONIST	IC50	6.16	IUPHAR
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	6.14	DRUG MATRIX
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.35	DRUG MATRIX
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.39	DRUG MATRIX
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN		Ki	5.15	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.35	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.52	CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	7.70	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	5.17	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.51	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.10	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.00	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.50	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.13	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.12	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.24	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.43	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.05	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	5.47	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.29	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	5.78	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.29	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	5.68	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	5.79	DRUG MATRIX
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	5.83	DRUG MATRIX
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	5.27	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.35	DRUG MATRIX
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN		Ki	5.11	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.57	DRUG MATRIX
Intermediate conductance calcium-activated potassium channel protein 4	Ion channel	O15554	KCNN4_HUMAN		IC50	7.15	CHEMBL
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN				WOMBAT-PK
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.16	DRUG MATRIX
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		IC50	4.52	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	5.13	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.60	DRUG MATRIX
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	5.76	DRUG MATRIX
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	4.71	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	7.80	DRUG MATRIX
Platelet-activating factor receptor	GPCR	P25105	PTAFR_HUMAN		Ki	4.65	DRUG MATRIX
Aromatase	Enzyme	P11511	CP19A_HUMAN		IC50	8.74	CHEMBL
Cysteinyl leukotriene receptor 1	GPCR	Q9Y271	CLTR1_HUMAN		Ki	4.78	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	4.16	DRUG MATRIX
Vasopressin V2 receptor	GPCR	P30518	V2R_HUMAN		IC50	5.60	CHEMBL
Substance-P receptor	GPCR	P25103	NK1R_HUMAN		Ki	5.06	DRUG MATRIX
Steroid 17-alpha-hydroxylase/17,20 lyase	Enzyme	P05093	CP17A_HUMAN		IC50	7.09	WOMBAT-PK
Potassium voltage-gated channel subfamily A member 3	Ion channel	P22001	KCNA3_HUMAN		IC50	5.22	CHEMBL
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	7.80	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	4.50	DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	4.18	DRUG MATRIX
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	7.85	DRUG MATRIX
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN		IC50	5.49	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme	Q16850	CP51A_HUMAN		IC50	6.89	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.92	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.47	DRUG MATRIX
C-C chemokine receptor type 4	GPCR	P51679	CCR4_HUMAN		IC50	5.80	CHEMBL
C-X-C chemokine receptor type 1	GPCR	P25024	CXCR1_HUMAN		IC50	5.70	CHEMBL
Transitional endoplasmic reticulum ATPase	Enzyme	P55072	TERA_HUMAN		IC50	5.85	CHEMBL
Malate dehydrogenase cytoplasmic	Enzyme	P40925	MDHC_HUMAN		IC50	4.46	CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase	Enzyme	Q9UNU6	CP8B1_HUMAN		IC50	6.10	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme		CP51_CANAL	INHIBITOR			CHEMBL	CHEMBL
Beta-lactamase	Enzyme		AMPC_ECOLI		IC50	4.70	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	5.11	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	4.91	DRUG MATRIX
Cysteinyl leukotriene receptor 1	GPCR		CLTR1_CAVPO		Ki	4.78	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	5.94	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	4.58	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme		CP51_MYCTU		Kd	6.70	CHEMBL
14-alpha sterol demethylase Cyp51A	Enzyme		Q4WNT5_ASPFU		Kd	5.32	CHEMBL
14-alpha sterol demethylase	Enzyme		Q96W81_ASPFM		Kd	6.99	CHEMBL
Indoleamine 2,3-dioxygenase 2	Enzyme		I23O2_MOUSE		IC50	5.23	CHEMBL
Mycocyclosin synthase	Enzyme		CP121_MYCTU		Kd	7.14	CHEMBL
Putative cytochrome P450 130	Enzyme		CP130_MYCTU		Kd	4.88	CHEMBL
Alpha-chymotrypsin	Enzyme		CTRA_BOVIN		IC50	4.07	CHEMBL
Indoleamine 2,3-dioxygenase 1	Enzyme		I23O1_MOUSE		IC50	4.29	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	4.75	CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	Enzyme		AT2A1_RABIT		Ki	4.46	CHEMBL

External reference:

ID	Source
4018265	VUID
N0000146595	NUI
D00282	KEGG_DRUG
202859	RXNORM
4018265	VANDF
C0009074	UMLSCUI
CHEBI:3764	CHEBI
CL6	PDB_CHEM_ID
CHEMBL104	ChEMBL_ID
DB00257	DRUGBANK_ID
D003022	MESH_DESCRIPTOR_UI
2812	PUBCHEM_CID
2330	IUPHAR_LIGAND_ID
2912	INN_ID
G07GZ97H65	UNII
1284	MMSL
4482	MMSL
d01236	MMSL
002916	NDDF
387325003	SNOMEDCT_US
5797005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-8146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Lotrisone	HUMAN PRESCRIPTION DRUG LABEL	2	0085-0924	CREAM	10 mg	TOPICAL	NDA	26 sections
Good Sense Athletes Footantifungal	HUMAN OTC DRUG LABEL	1	0113-0857	CREAM	1 g	TOPICAL	OTC monograph final	13 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0133	CREAM	10 mg	TOPICAL	ANDA	20 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0258	CREAM	10 mg	TOPICAL	ANDA	27 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0370	LOTION	10 mg	TOPICAL	ANDA	20 sections
Fungicure Liquid Gel	HUMAN OTC DRUG LABEL	1	0295-1363	LIQUID	10 mg	TOPICAL	OTC monograph final	9 sections
Fungicure Manicure Pedicure Anti Fungal	HUMAN OTC DRUG LABEL	1	0295-6307	LIQUID	1 mg	TOPICAL	OTC monograph final	10 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
WALGREENS CLOTRIMAZOLE	HUMAN OTC DRUG LABEL	1	0363-1299	CREAM	1 g	TOPICAL	OTC monograph final	11 sections
athletes foot	HUMAN OTC DRUG LABEL	1	0363-1857	CREAM	1 g	TOPICAL	OTC monograph final	13 sections
Walgreens Clotrimazole 3	HUMAN OTC DRUG LABEL	1	0363-2062	CREAM	2 g	VAGINAL	NDA	16 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-2105	CREAM	10 mg	TOPICAL	OTC MONOGRAPH FINAL	14 sections
Ringworm	HUMAN OTC DRUG LABEL	1	0363-2107	CREAM	10 mg	TOPICAL	OTC MONOGRAPH FINAL	14 sections
Walgreens Jock Itch	HUMAN OTC DRUG LABEL	1	0363-2109	CREAM	10 mg	TOPICAL	OTC MONOGRAPH FINAL	14 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-3492	LIQUID	1 mg	TOPICAL	OTC monograph final	8 sections
Walgreens Clotrimazole Antifungal	HUMAN OTC DRUG LABEL	1	0363-7412	CREAM	1 g	TOPICAL	OTC monograph final	11 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0472-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
ClotrimazoleAntifungal	HUMAN OTC DRUG LABEL	1	0472-0350	CREAM	10 mg	TOPICAL	OTC monograph final	13 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0472-0379	CREAM	10 mg	TOPICAL	ANDA	24 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0536-1181	SOLUTION	1 g	TOPICAL	OTC monograph final	13 sections
Rugby Clotrimazole Antifungal Cream	HUMAN OTC DRUG LABEL	1	0536-1265	CREAM	1 g	TOPICAL	OTC monograph final	12 sections
RUGBY ANTIFUNGAL CLOTRIMAZOLE	HUMAN OTC DRUG LABEL	1	0536-1272	CREAM	0.01 g	TOPICAL	OTC monograph final	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0107	LOZENGE	10 mg	ORAL	ANDA	18 sections
Major Clotrimazole	HUMAN OTC DRUG LABEL	1	0904-7822	CREAM	10 mg	TOPICAL	OTC monograph final	11 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	10135-671	SOLUTION	1 g	TOPICAL	OTC monograph final	13 sections
Lotrimin	HUMAN OTC DRUG LABEL	1	11523-0963	CREAM	10 mg	TOPICAL	OTC monograph final	14 sections
LotriminAntifungal	HUMAN OTC DRUG LABEL	1	11523-1125	CREAM	10 mg	TOPICAL	OTC monograph final	14 sections
Lotrimin	HUMAN OTC DRUG LABEL	1	11523-6549	CREAM	10 mg	TOPICAL	OTC monograph final	14 sections